AUPH Aurinia Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AUPH

Price (delayed)

$8.84

Market cap

$1.27B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.53

Enterprise value

$1.32B

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The ...

Highlights
The revenue has increased by 23% YoY
Aurinia Pharmaceuticals's debt has decreased by 8% QoQ
Aurinia Pharmaceuticals's EPS has increased by 36% YoY but it has decreased by 6% QoQ
The net income has increased by 33% YoY but it has decreased by 6% from the previous quarter
The quick ratio has declined by 49% year-on-year and by 15% since the previous quarter
AUPH's equity is down by 7% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.auriniapharma.com
Peers: LXRX REGN QURE NVAX

Key stats

What are the main financial stats of AUPH
Market
Shares outstanding
143.61M
Market cap
$1.27B
Enterprise value
$1.32B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.24
Price to sales (P/S)
7.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.29
Earnings
Revenue
$158.85M
EBIT
-$74.78M
EBITDA
-$67.86M
Free cash flow
-$38.27M
Per share
EPS
-$0.53
Free cash flow per share
-$0.27
Book value per share
$2.73
Revenue per share
$1.11
TBVPS
$3.85
Balance sheet
Total assets
$555.01M
Total liabilities
$163.14M
Debt
$93.21M
Equity
$391.88M
Working capital
$352.58M
Liquidity
Debt to equity
0.24
Current ratio
5.77
Quick ratio
5.09
Net debt/EBITDA
-0.69
Margins
EBITDA margin
-42.7%
Gross margin
93.6%
Net margin
-48.6%
Operating margin
-56.7%
Efficiency
Return on assets
-15.2%
Return on equity
-19.5%
Return on invested capital
-17.8%
Return on capital employed
-15.5%
Return on sales
-47.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AUPH stock price

How has the Aurinia Pharmaceuticals stock price performed over time
Intraday
0.34%
1 week
2.79%
1 month
6.63%
1 year
84.94%
YTD
104.63%
QTD
13.77%

Financial performance

How have Aurinia Pharmaceuticals's revenue and profit performed over time
Revenue
$158.85M
Gross profit
$148.74M
Operating income
-$90.12M
Net income
-$77.19M
Gross margin
93.6%
Net margin
-48.6%
Aurinia Pharmaceuticals's net margin has increased by 46% YoY but it has decreased by 7% QoQ
The operating margin has increased by 37% YoY but it has decreased by 9% from the previous quarter
The net income has increased by 33% YoY but it has decreased by 6% from the previous quarter
The revenue has increased by 23% YoY

Growth

What is Aurinia Pharmaceuticals's growth rate over time

Valuation

What is Aurinia Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.24
P/S
7.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.29
Aurinia Pharmaceuticals's EPS has increased by 36% YoY but it has decreased by 6% QoQ
The price to book (P/B) is 31% lower than the 5-year quarterly average of 4.7 but 7% higher than the last 4 quarters average of 3.0
AUPH's equity is down by 7% year-on-year
The stock's P/S is 100% less than its 5-year quarterly average of 1888.8 but 2.9% more than its last 4 quarters average of 7.7
The revenue has increased by 23% YoY

Efficiency

How efficient is Aurinia Pharmaceuticals business performance
AUPH's ROIC has soared by 50% year-on-year and by 4.8% since the previous quarter
Aurinia Pharmaceuticals's return on sales has increased by 47% YoY but it has decreased by 6% QoQ
The company's return on assets rose by 34% YoY but it fell by 2.7% QoQ
The ROE has increased by 25% YoY but it has decreased by 8% from the previous quarter

Dividends

What is AUPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AUPH.

Financial health

How did Aurinia Pharmaceuticals financials performed over time
The total liabilities has soared by 151% YoY and by 4.2% from the previous quarter
The quick ratio has declined by 49% year-on-year and by 15% since the previous quarter
Aurinia Pharmaceuticals's debt is 76% lower than its equity
Aurinia Pharmaceuticals's debt has decreased by 8% QoQ
The company's debt to equity fell by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.